Roland R. Griffiths

Roland R. Griffiths
Name	Roland R. Griffiths
Birth date	1946
Birth place	Lawrence, Kansas
Death date	2023
Occupation	Psychopharmacologist, Professor
Employer	Johns Hopkins University
Known for	Research on psychedelics, psilocybin, consciousness studies

Roland R. Griffiths was an American psychopharmacologist and clinical researcher noted for pioneering modern human laboratory investigations of classic psychedelics and their therapeutic potential. He held appointments at Johns Hopkins University and directed laboratories that bridged clinical psychiatry, neuroscience, and psychopharmacology, contributing to renewed scientific and regulatory interest in substances such as psilocybin and LSD. His work influenced clinical trials, policy discussions, and cultural perceptions across psychiatry, neuroscience, and psychedelic research communities.

Early life and education

Griffiths was born in Lawrence, Kansas, and received early schooling that preceded undergraduate study at University of Kansas and graduate training at Purdue University and Indiana University School of Medicine where he completed doctoral and postdoctoral work integrating psychopharmacology, behavioral pharmacology, and clinical research. He trained in psychopharmacology under mentors associated with institutions such as National Institutes of Health, acquiring expertise that connected laboratory methods used at Rockefeller University and clinical protocols used at Massachusetts General Hospital. His formative education included exposure to paradigms promoted by researchers at Harvard Medical School and Yale University.

Academic and professional career

Griffiths joined Johns Hopkins University where he established the [Johns Hopkins Center for Psychedelic and Consciousness Research], coordinating interdisciplinary teams drawing on fields represented at National Institute on Drug Abuse, National Institute of Mental Health, American Psychiatric Association, and Society for Neuroscience. He held faculty appointments in departments linked to Johns Hopkins School of Medicine and worked with collaborators from Imperial College London, University of California, San Francisco, Mount Sinai Health System, and Columbia University. His laboratory applied clinical trial designs similar to those used at University of Oxford and Stanford University for translational psychopharmacology, and he served on advisory panels with members from Food and Drug Administration, Multidisciplinary Association for Psychedelic Studies, and philanthropic entities such as the Pew Charitable Trusts.

Research on psychedelics and major findings

Griffiths conducted randomized, double-blind human laboratory studies of psilocybin and other classic psychedelics, employing outcome measures and neuroimaging approaches comparable to those used by teams at Imperial College London and Yale University. His major findings included demonstration of rapid, sustained antidepressant and anxiolytic effects in trials for depressive and anxiety disorders, outcomes paralleling results from investigators at Johns Hopkins University and New York University. He characterized mystical-type experiences measured with instruments developed in conjunction with researchers connected to Harvard Medical School, University of California, Los Angeles, and Columbia University. Neurobiological investigations linked acute subjective effects to brain network dynamics studied by scientists at Massachusetts Institute of Technology, Max Planck Institute for Human Cognitive and Brain Sciences, and University College London. His work influenced clinical protocols for psilocybin-assisted psychotherapy alongside researchers at Mount Sinai Health System, University of Zurich, and University of California, San Diego, informing regulatory pathways considered by the Food and Drug Administration and discussions at the World Health Organization.

Publications and awards

Griffiths authored and coauthored numerous peer-reviewed articles in journals including The New England Journal of Medicine, JAMA Psychiatry, Nature Medicine, Psychopharmacology, and Proceedings of the National Academy of Sciences. He contributed chapters in volumes associated with editors from Oxford University Press and Cambridge University Press, and his work was cited in policy reviews from National Academies of Sciences, Engineering, and Medicine. Honors included recognition from organizations such as the American College of Neuropsychopharmacology, the Royal Society of Medicine, and awards analogous to those given by Society for Neuroscience and American Psychological Association for contributions to psychopharmacology and translational research. He served on editorial boards with peers from Biological Psychiatry, The Lancet Psychiatry, and Frontiers in Psychiatry.

Public engagement and influence

Griffiths engaged with media outlets and public forums including appearances in programs produced by PBS, interviews in The New York Times, debates featured in The Guardian, and contributions to documentary projects linked to BBC and Netflix. He participated in panels at conferences hosted by TED, World Economic Forum, American Psychiatric Association Annual Meeting, and symposia at Society for Neuroscience where he discussed clinical trial ethics, safety frameworks, and therapeutic models used in collaborations with Multidisciplinary Association for Psychedelic Studies and philanthropic initiatives such as those by the Heffter Research Institute. His advocacy for rigorous clinical methodology influenced policy conversations involving representatives from the Drug Enforcement Administration and the Food and Drug Administration.

Personal life and death

Griffiths lived in the Baltimore area while maintaining collaborations across institutions such as Johns Hopkins Bloomberg School of Public Health and research networks including ClinicalTrials.gov affiliates. Colleagues and family noted his mentorship of trainees who later joined faculties at Harvard Medical School, Yale University School of Medicine, Stanford University School of Medicine, and University of California, San Francisco. He died in 2023, and tributes were published by institutions including Johns Hopkins University, Nature, The New York Times, and professional societies such as the American Psychiatric Association and American College of Neuropsychopharmacology.

Category:American psychopharmacologists